A new biotech company has raised $25 million to finance research on the effects of psychedelics and other drugs on depression and other mental illnesses.
Plant and Drug Research Studies
A new biotech company has raised $25 million to finance research on the effects of psychedelics and other drugs on depression and other mental illnesses.
Researchers Want Doctors to Be Able to Prescribe Magic Mushrooms for Depression Motherboard
A new study out of Johns Hopkins University seeks to reclassify psilocybin mushrooms since they have low potential for abuse and few risks of dependence.
Psychedelic Mushrooms: Scientists Propose Making Them Legal Inverse
Magic mushrooms may be poised to make a magical transformation within the law. In their recent review in Neuropharmacology, a team of researchers from …
Magic Mushrooms Could Be Reclassified, Experts Say Newsweek
Psilocybin is increasingly being recognized by scientists as potentially effective treatments for a number of psychological disorders, such as addiction and …
“Magic” Psilocybin Mushrooms Deserve New Legal Status, Argue Scientists Inverse
Psychedelic “magic” mushrooms may become legal in the next decade if some psychologists and psychiatrists have anything to say about it. The active chemical …
Hopkins researchers recommend reclassifying psilocybin, the drug in ‘magic’ mushrooms, from schedule I to schedule IV The Hub at Johns Hopkins
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical …
Could “Magic Mushrooms” Help You Stop Smoking? TheFix.com
A new study examined whether psilocybin could help long-time smokers put down their butts for good.
FDA Approves Landmark Psilocybin Trial for Treatment-Resistant Depression MD Magazine
The phase 2b dose-ranging trial will involve 216 patients across 12-15 research sites in North America and Europe, beginning in the UK later this month.
FDA approves ‘magic mushroom’ psilocybin therapy trial for treatment-resistant depression OutSourcing-Pharma.com
Compass Pathways has received approval from the US FDA for a clinical trial using psilocybin, the active ingredient in ‘magic mushrooms.’ A Phase IIb study will …
Science is testing claims about psilocybin microdoses, and finding some truth STAT
Psilocybin microdoses have no effect on problem-solving and rational thinking but do improve a form of thinking underlying creativity, a study suggests.